<DOC>
	<DOC>NCT01649297</DOC>
	<brief_summary>The aim of this study is to investigate the efficacy and safety of two doses (high and low) of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) and insufficient glycaemic control. Both doses may be given once daily or split to a twice daily dosage. This results in 4 different dosage regimens of empagliflozin (high dose once daily or split vs. low dose once daily or split). This is done to evaluate whether a twice daily dose regimen of empagliflozin results in a loss of efficacy relative to once daily dosing when given on top of metformin background therapy.</brief_summary>
	<brief_title>A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criteria: 1. confirmed diagnosis of T2DM 2. Glycated hemoglobin (HbA1c) &gt;=7.0 and &lt;=10/0% at Visit 1 3. Metformin therapy (at least 1500 mg/day, BID) 4. age&gt;=18 at Visit 1 5. body mass index &lt;=45 kg/m2 Exclusion criteria: 1. estimated creatinine clearance rate (eCCr) &lt;60 ml/min (CockcroftGault formula) screening and/or runin 2. a confirmed glucose level &gt;240 mg/dl (&gt;13.3 mmol/L) after an overnight fast during placebo runin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>